DoMore Diagnostics announced that it received CE mark approval in Europe for its Histotype Px Colorectal deep learning algorithm.
Oslo, Norway-based DoMore designed its Histotype Px Colorectal deep learning algorithm to predict colorectal cancer patient outcomes based on analysis of digital histology images.
The company said in a news release that the algorithm, which builds on research led by the Institute for Cancer Genetics and Informatics at Oslo University Hospital, represents the first CE-marked product to utilize artificial intelligence (AI) to predict patient outcomes based on advanced image analysis.
Analysis with the Histotype Px Colorectal deep learning algorithm is conducted on high-resolution scans from standard H&E stained slides to provide shorter turnaround times, DoMore Diagnostics said.
Results from an early version of the algorithm were published in The Lancet, while the company has spent the last year applying improvements and developments for the now commercially available product. DoMore Chair Dr. Tomas Nordheim Alme said it offers clinicians and patients the ability to receive patient risk information immediately after surgery, representing an improvement on markers today with turnaround being weeks to even months faster with the algorithm.
“We are very excited about this CE mark as it enables clinical use across Europe. The product fits well within the existing hospital workflow and adds real value to the various digital pathology platforms available,” DoMore Diagnostics CEO and co-founder Torbjørn Furuseth said in the release. “This product makes so much sense for patients, healthcare providers and payers. With the simplicity and unmatched turnaround time we can provide physicians with additional valuable information to make the best treatment decisions for patients. We believe prognostic and predictive algorithms will unlock the full value of digital pathology.”